CTXR - Rasio cepet Citius Pharmaceuticals Inc.

Citius Pharmaceuticals (CTXR) is targeting long-term expansion within the hospital therapy and Lymphir oncology segments to capture the US market. The stock price trend, which currently stands at 0.39, confirms the status of a brand valued by physicians for its effective infection control methods. Fully utilized contract capacities and rigorous audits of sterile lines ensure business stability.

This indicator assesses the issuer's ability to instantaneously settle short-term obligations using only cash and accounts receivable, excluding slow-moving inventories. By analyzing the quick ratio, an investor can gauge the financial cushion of Citius Pharmaceuticals (CTXR), which is critical for sustaining the development and distribution of the innovative drug Mino-Lok, designed to minimize catheter-related infection risks in intensive care.